These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 28588220)

  • 1. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Liu J; Li L; Li S; Jia P; Deng K; Chen W; Sun X
    Sci Rep; 2017 Jun; 7(1):2824. PubMed ID: 28588220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial.
    Arshad M; Hoda F; Siddiqui NA; Najmi AK; Ahmad M
    Drug Res (Stuttg); 2024 Sep; 74(7):307-313. PubMed ID: 38991530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis.
    Bapir R; Bhatti KH; Eliwa A; García-Perdomo HA; Gherabi N; Hennessey D; Magri V; Mourmouris P; Ouattara A; Perletti G; Philipraj J; Stamatiou K; Tolani MA; Tzelves L; Anker SD; Trinchieri A; Buchholz N
    Arch Ital Urol Androl; 2023 Jun; 95(2):11509. PubMed ID: 37314421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
    Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
    Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM
    Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
    Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
    Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A population-based self-controlled case-series study.
    Kang M; Heo KN; Ah YM; Yang BR; Lee JY
    Maturitas; 2021 Aug; 150():30-36. PubMed ID: 34274073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
    Liu Y; An C; Liu P; Yang F; Zhao Q
    Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
    Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
    Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
    Dave CV; Schneeweiss S; Patorno E
    Diabetes Obes Metab; 2019 Feb; 21(2):434-438. PubMed ID: 30207042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
    Guo M; Ding J; Li J; Wang J; Zhang T; Liu C; Huang W; Long Y; Gao C; Xu Y
    Diabetes Obes Metab; 2018 Aug; 20(8):1977-1982. PubMed ID: 29573118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
    Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A
    Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.